Eiger Has Positive Data For Its COVID-19 Drug, But Faces Uncertain Market

 
• By Alaric DeArment
  
3D_Coronavirus
Eiger announced data from its Phase III trial of peginterferon lambda in non-hospitalized COVID-19 patients. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip